Atala speaks at MHS 2012
Dr. Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine, led the team that developed the first lab-grown organ, a bladder, to be implanted into a human. He continues to work in tissue engineering and printable organs, perform surgery and run a clinic at North Carolina Baptist Hospital. Here he explains the history of regenerative medicine at the 2012 Military Health System Conference Jan. 30, 2012, at National Harbor, Md.

NATIONAL HARBOR, Md. (Army News Service, Feb. 1, 2012) -- The Armed Forces Institute of Regenerative Medicine is working with consortiums toward growing body parts for wounded warriors.

At the 2012 Military Health System Conference, from Jan. 30 to Feb. 2, Dr. Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine, explained how success doesn't come easy.

Atala led a team that developed the first lab-grown organ, a bladder, that was implanted into a boy more than a decade ago.

"The work in our presentation today has been performed by more than 1,000 researchers over the past 20 years," he said.

In 1995, the Vacanti mouse, named after Dr. Charles Vacanti who created the "ear" grown on the back of this mouse, was a laboratory mouse that had what looked like a human ear gown on its back. This "ear" was actually an ear-shaped cartilage structure grown by seeding bovine cartilage cells into a biodegradable ear-shaped mold.

The Vacanti mouse ear has still not been used on a human.

One thing is quite clear," Joachim Kohn cited on its development, "a human being has two ears." You can't walk around with a round ear and a pointy ear."

"This is what killed the process in 1996. Time Magazine showed the mouse with the nicely shaped ear but they didn't show the 10 mice where the ear was all screwed up," said Kohn who is with the Armed Forces Institute of Regenerative Medicine and also heads the consortium for Rutgers University.

BRIEF HISTORY OF REGENERATIVE MEDICINE

"When we look at regenerative medicine, we really have to look back at the field of organ transplantation which dates back to 1954 with the first organ transplant, a kidney," Atala said.

Many advances have been made since that single event, he said.

"Yet we're still dealing with a lot of the same challenges in terms of organ rejection and shortage, and that's why we began looking at the field of regenerative medicine for some of these answers," he said.

Regenerative medicine is not a new field.

One of the textbooks, "The Culture of Organs," published in 1938, was co-authored by Alexis Carrel and Charles A. Lindbergh, the same Lindbergh who flew across the Atlantic back in the 1920s. He worked at the Rockefeller Institute in New York with Carrel, a surgeon, who designed blood vessel Dacron grafts, still in use today.

"The first actual clinical application dates back to 1981 when a patient at Massachusetts General Hospital in Boston had a burn. They took a very small piece of skin, grew the cells outside the body, placed those cells on a matrix, placed that over the wound which helped it to heal faster. This was the very first time that the patient's own cells were actually used for therapy," Atala said.

THREE MAJOR CHALLENGES

With a field that's been around so long, why have there been so few clinical advances?

"Three major challenges, if I were to point to the most relevant: an inability to expand normal primary human cells outside the body, inadequate bio materials, and vascularity. Just 30 years ago, we did not have the knowledge to grow cells outside the body. We now can take these cells that before could not be expanded, and by knowing where the progenitor cells were located and knowing the growth factor biology, we could now expand these cells very readily," Atala said.

"We can take a very small piece of tissue, less than half the size of a postage stamp and by day 60 have enough cells to cover a football field. But even in 2012, with all the advances that we have made scientifically throughout the world and all the scientists working in cell biology, there are still certain cell types that we cannot grow outside the body from patients," he said.

The second challenge was bio materials.

"We started looking at different bio materials. Very simply said, if you're trying to replace a piece of bone, you're going to use a very different bio material than if you're trying to replace a blood vessel," Atala said.

The third challenge was vascularity. How can these cells grow and expand inside the body?

"Well, how does nature do it? Nature does it by branching -- from the lowest forms of life, such as algae which you may see at the bottom of the ocean floor, to a leaf, to the branches of a tree, to the blood vessel. In fact, branching is a solution to nutrient diffusion. And that is why many different laboratories started working on scaffold systems that under a naked eye look like a piece of your shirt or your blouse. Under a microscope it has this branching pattern which allows the cells to lay down like a hammock supporting this cell sheet that then provides the porosity necessary," Atala said.

The easiest tissue formation, he said, is skin. Tubular organs are not as easy, and hollow non-tubular organs, such as the vagina, bladder and uterus, are complex. The most complex are solid organs, such as the penis, liver and kidney, which so far are not yet ready for human regeneration.

AFIRM

The Armed Forces Institute of Regenerative Medicine is one of the major outgrowths of the nearly 10-year war in Iraq and Afghanistan.

Created by the U.S. Army Medical Research & Materiel Command in 2007, AFIRM develops and oversees a network of academic research teams working on advanced treatment options for severely wounded warriors.

The AFIRM director is Terry Irgens, a retired Navy pharmacist, hospital executive officer, and medical logistician. In an article which first appeared in "The Year in Veterans Affairs & Military Medicine: 2011-2012 Edition," he explained the genesis of AFIRM.

"When this began, we had a lot of wounded warriors coming back with severe disfigurations, missing limbs, and other injuries that were unusual because, in the past, the survival rate for those was not as great as today," Irgens explained.

"A lot of research going on in regenerative medicine was 'way out there,' so to speak, but up and coming. DOD held some conferences on the topic and experts explained what was being done in growing organs, tissue growth, different scaffolds for making ears and such," he said.

During an April 17, 2008 Pentagon press conference, then Army Surgeon General Lt. Gen. Eric Schoomaker announced the establishment of AFIRM, after first putting out a project announcement in 2007 which focused on five areas: burns, scarless wound treatment, limb and digit salvage, compartment syndrome repair, and wounds to the face.

At the same time, President George W. Bush got interested in this technology and was able to double the funding, so awards were given to two consortia instead of only one, each of which covered all five focus areas."

"The primary driver was the number of casualties returning, which was a good thing in terms of a high battlefield survival rate, but they were coming back with catastrophic injuries that required new technologies and treatments," Irgens said.

The primary cause of injuries during the past 10 years of conflict has been the improvised explosive device.

"Improved armor and battlefield care have kept alive wounded warfighters who would not have survived any previous war, but (this) also led to a substantial increase in severe wounds to the face and limbs. The pressure on military medicine then became a way to improve the survivors' quality of life," Irgens said.

"Bringing new therapies to the wounded warrior requires persistence, stable leadership, some funding, and a lot of patience over the seven-to-10-year medical development cycle," said Kohn.

Page last updated Fri February 3rd, 2012 at 08:49